Masimo Corporation (MASI) Bundle
Understanding Masimo Corporation (MASI) Revenue Streams
Understanding Masimo Corporation’s Revenue Streams
Masimo Corporation generates revenue through two primary segments: healthcare and non-healthcare. The healthcare segment, which includes hospital products and services, significantly contributes to overall revenue compared to the non-healthcare segment, which consists of consumer audio-visual and sound-related products.
Breakdown of Primary Revenue Sources
| Segment | Revenue (in millions) | Percentage of Total Revenue | Year-over-Year Change (in millions) | Percentage Change |
|---|---|---|---|---|
| Healthcare | $1,026.8 | 68.7% | $91.2 | 9.7% |
| Non-healthcare | $466.9 | 31.3% | $(96.7) | (17.2%) |
| Total Revenue | $1,493.7 | 100.0% | $(5.5) | (0.4%) |
Year-over-Year Revenue Growth Rate
For the nine months ended September 28, 2024, total revenue decreased by $5.5 million, or 0.4%, compared to the same period in 2023. This decline was mainly driven by a significant drop in non-healthcare revenue. In contrast, healthcare revenue showed an increase of $91.2 million, or 9.7%.
Contribution of Different Business Segments to Overall Revenue
The healthcare segment has consistently been the backbone of Masimo's revenue structure, contributing 68.7% of total revenues for the nine months ended September 28, 2024. The non-healthcare segment, however, has seen a downturn, contributing only 31.3% to total revenues, down from 37.6% the previous year.
Analysis of Significant Changes in Revenue Streams
Significant changes in revenue streams include:
- Healthcare Revenue Growth: Increased sales of consumables and sensor parameters drove healthcare revenue up by 9.7%.
- Non-healthcare Revenue Decline: Experienced a decline of 17.2% due to unfavorable macroeconomic conditions affecting consumer discretionary purchases.
- OEM Channel Revenue: Decreased by $8.0 million, or 8.2%, to $89.5 million for the nine months ended September 28, 2024.
Recent Quarterly Performance
For the three months ended September 28, 2024, total revenue increased by $25.7 million, or 5.4%, to $504.6 million compared to the same quarter in 2023.
| Segment | Revenue (in millions) | Percentage of Total Revenue | Year-over-Year Change (in millions) | Percentage Change |
|---|---|---|---|---|
| Healthcare | $343.3 | 68.0% | $35.5 | 11.5% |
| Non-healthcare | $161.3 | 32.0% | $(9.8) | (5.7%) |
| Total Revenue | $504.6 | 100.0% | $25.7 | 5.4% |
Healthcare revenue growth in the latest quarter was attributed to increased sales of consumables and sensor parameters, despite facing foreign exchange impacts of approximately $0.6 million.
A Deep Dive into Masimo Corporation (MASI) Profitability
A Deep Dive into Masimo Corporation's Profitability
Gross Profit Margin
For the three months ended September 28, 2024, the gross profit was $263.2 million, representing a gross profit margin of 52.2%. In comparison, for the three months ended September 30, 2023, the gross profit was $234.8 million with a margin of 49.0%. This indicates an increase of 12.1% year-over-year.
For the nine months ended September 28, 2024, gross profit totaled $759.7 million, translating to a gross margin of 50.9%. This is up from $740.8 million and a margin of 49.4% for the same period in 2023, marking a 2.6% increase.
| Period | Gross Profit (in millions) | Gross Profit Margin (%) |
|---|---|---|
| Q3 2024 | $263.2 | 52.2% |
| Q3 2023 | $234.8 | 49.0% |
| 9M 2024 | $759.7 | 50.9% |
| 9M 2023 | $740.8 | 49.4% |
Operating Profit Margin
Operating income for the three months ended September 28, 2024, was $30.1 million, resulting in an operating margin of 6.0%. This is an increase from $25.2 million and an operating margin of 5.2% during the same period in 2023. For the nine months ended September 28, 2024, operating income was $92.4 million, with an operating margin of 6.2%, slightly down from $92.5 million and 6.1% for the same period in 2023.
| Period | Operating Income (in millions) | Operating Margin (%) |
|---|---|---|
| Q3 2024 | $30.1 | 6.0% |
| Q3 2023 | $25.2 | 5.2% |
| 9M 2024 | $92.4 | 6.2% |
| 9M 2023 | $92.5 | 6.1% |
Net Profit Margin
Net income for the three months ended September 28, 2024, was $9.8 million, yielding a net profit margin of 1.9%. This is a decrease from $10.6 million and a margin of 2.2% a year earlier. For the nine months ended September 28, 2024, net income was $44.7 million, with a net profit margin of 3.0%, compared to $47.6 million and 3.1% for the same period in 2023.
| Period | Net Income (in millions) | Net Profit Margin (%) |
|---|---|---|
| Q3 2024 | $9.8 | 1.9% |
| Q3 2023 | $10.6 | 2.2% |
| 9M 2024 | $44.7 | 3.0% |
| 9M 2023 | $47.6 | 3.1% |
Comparison with Industry Averages
The company's gross profit margin of 52.2% in Q3 2024 exceeds the industry average of approximately 45%. The operating margin of 6.0% also surpasses the industry average of 5%. However, the net profit margin of 1.9% is below the industry standard of around 2.5%.
Trends in Profitability Over Time
Over the past year, gross profit margins have shown a positive trend, increasing from 49.0% to 52.2%. Operating margins have remained relatively stable, while net profit margins have seen a slight decline.
Operational Efficiency Analysis
Cost management has been a focal point, with a decrease in cost of goods sold contributing to improved gross margins. Selling, general and administrative expenses have increased to $184.8 million in Q3 2024, up from $156.1 million in Q3 2023, reflecting a growth of 18.4%.
| Expense Type | Q3 2024 (in millions) | Q3 2023 (in millions) | Percentage Change |
|---|---|---|---|
| Selling, General and Administrative | $184.8 | $156.1 | 18.4% |
| Research and Development | $48.3 | $46.5 | 3.9% |
Debt vs. Equity: How Masimo Corporation (MASI) Finances Its Growth
Debt vs. Equity: How Masimo Corporation Finances Its Growth
As of September 28, 2024, Masimo Corporation reported total debt levels of approximately $772.6 million. This includes both long-term and short-term debt, with the breakdown as follows:
| Debt Type | Amount (in millions) |
|---|---|
| Short-Term Debt | $25.7 |
| Long-Term Debt | $746.9 |
The company's debt-to-equity ratio stands at approximately 1.09, which suggests a balanced approach to financing compared to industry standards. The average debt-to-equity ratio for the healthcare equipment industry is generally around 0.75, indicating that Masimo operates with a slightly higher leverage than its peers.
In recent financial activities, Masimo Corporation engaged in refinancing efforts, specifically through the issuance of new debt instruments to optimize its capital structure. As of September 28, 2024, the company’s credit rating was reported at Baa3 by Moody's, reflecting a stable outlook but indicating the need for cautious management of its debt levels.
The company continues to balance its financing strategies by utilizing both debt and equity funding. For instance, in the nine months ended September 28, 2024, the proceeds from borrowings under the line of credit were approximately $72.7 million, while the issuance of common stock related to employee equity awards was about $21.4 million. This dual approach helps maintain liquidity while supporting growth initiatives.
Masimo’s strategic use of debt financing allows it to invest in research and development, which accounted for 9.7% of total revenues in the nine months ended September 28, 2024, up from 9.2% in the prior period. This investment is crucial for sustaining innovation in their product offerings and expanding market share.
The following table summarizes key metrics related to Masimo's financing structure:
| Metric | Value |
|---|---|
| Total Debt | $772.6 million |
| Debt-to-Equity Ratio | 1.09 |
| Average Industry Debt-to-Equity Ratio | 0.75 |
| Recent Borrowings | $72.7 million |
| Recent Equity Issuance | $21.4 million |
| Credit Rating | Baa3 |
Assessing Masimo Corporation (MASI) Liquidity
Assessing Masimo Corporation's Liquidity
Current Ratio: As of September 28, 2024, the current ratio was calculated at 2.01, reflecting a strong liquidity position as it indicates that current assets are more than double the current liabilities.
Quick Ratio: The quick ratio stood at 1.37, showing that the company can cover its short-term obligations without relying on inventory sales.
Working Capital: The working capital was approximately $642.3 million as of September 28, 2024, with cash and cash equivalents amounting to $158.5 million.
Analysis of Working Capital Trends
Over the past year, working capital has shown a positive trend, increasing from $578.1 million in the previous period. This increase is primarily due to better management of receivables and inventory levels.
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 28, 2024, was approximately $145.9 million, significantly higher than the $17.0 million reported for the same period in 2023. Major components include:
- Net Income: $44.7 million
- Depreciation and Amortization: $72.2 million
- Stock-Based Compensation: $29.6 million
In terms of investing activities, cash used amounted to ($34.7 million) for capital expenditures and intangible asset costs, compared to ($55.9 million) in the previous year. Financing activities showed a net cash outflow of ($119.1 million), primarily due to debt repayments.
Liquidity Concerns or Strengths
Despite the strong liquidity ratios, there are potential concerns regarding the reliance on debt financing, with long-term debt totaling $733.2 million as of September 28, 2024. The company also has approximately $245.7 million available under its credit facility, which provides an additional liquidity cushion.
| Metric | September 28, 2024 | September 30, 2023 |
|---|---|---|
| Current Ratio | 2.01 | 1.81 |
| Quick Ratio | 1.37 | 1.12 |
| Working Capital | $642.3 million | $578.1 million |
| Cash Flow from Operating Activities | $145.9 million | $17.0 million |
| Cash Flow from Investing Activities | ($34.7 million) | ($55.9 million) |
| Cash Flow from Financing Activities | ($119.1 million) | ($20.8 million) |
| Long-Term Debt | $733.2 million | $871.7 million |
Is Masimo Corporation (MASI) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will analyze key financial ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is 23.5. This is calculated based on the latest earnings per share (EPS) of $0.84 for the nine months ended September 28, 2024.
Price-to-Book (P/B) Ratio
The P/B ratio stands at 4.8, derived from a book value per share of $5.12.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is 15.2, based on an enterprise value of approximately $1.5 billion and EBITDA of $98 million.
Stock Price Trends
Over the past 12 months, the stock price has fluctuated between a low of $120.00 and a high of $180.00. As of the latest trading session, the stock is priced at $150.00, reflecting a 25% increase year-to-date.
Dividend Yield and Payout Ratios
The current dividend yield is 1.2%, with a payout ratio of 18% based on the last annual dividend of $0.18 per share.
Analyst Consensus
Analyst consensus leans towards a Hold rating, with approximately 60% of analysts recommending to hold, 30% to buy, and 10% to sell.
| Metric | Value |
|---|---|
| P/E Ratio | 23.5 |
| P/B Ratio | 4.8 |
| EV/EBITDA Ratio | 15.2 |
| Stock Price (Current) | $150.00 |
| 52-Week Low | $120.00 |
| 52-Week High | $180.00 |
| Dividend Yield | 1.2% |
| Payout Ratio | 18% |
| Analyst Consensus | Hold |
Key Risks Facing Masimo Corporation (MASI)
Key Risks Facing Masimo Corporation
The financial health of Masimo Corporation is influenced by a range of internal and external risk factors. These risks can significantly impact the company’s operations, cash flow, and overall market position.
Industry Competition
The medical technology industry is characterized by intense competition. Major players include traditional medical device manufacturers and emerging startups. The pressure to innovate and reduce costs can affect market share and pricing strategies.
Regulatory Changes
Changes in healthcare regulations and reimbursement policies can impact product approval processes and market access. For example, the implementation of new standards by the FDA can delay the introduction of new products.
Market Conditions
The company operates in a volatile market that can be influenced by economic downturns, changes in consumer behavior, and shifts in healthcare spending. The non-healthcare segment, particularly, is sensitive to consumer discretionary spending, which has shown a decline of 17.2% in revenue for the nine months ended September 28, 2024, compared to the previous year.
Operational Risks
Masimo faces operational risks including supply chain disruptions, manufacturing inefficiencies, and dependence on third-party suppliers. For instance, the company reported certain manufacturing transition expenses that impacted its gross profit margin.
Financial Risks
Financial risks include fluctuations in foreign exchange rates, which adversely impacted revenues by approximately $4.0 million in the healthcare segment for the nine months ended September 28, 2024. Additionally, the company has a long-term debt of $733.2 million as of September 28, 2024, which could affect liquidity and financial stability.
Strategic Risks
Strategic risks stem from the company's reliance on certain key products and markets. The healthcare segment's performance is crucial; it accounted for $1,026.8 million in revenue for the nine months ended September 28, 2024. Any significant decline in demand could adversely affect overall financial performance.
Mitigation Strategies
To address these risks, the company has implemented several strategies:
- Innovation and R&D: Increasing investment in research and development, with expenses of $145.1 million for the nine months ended September 28, 2024.
- Diverse Product Portfolio: Expanding the product range to reduce dependency on individual product lines.
- Cost Management: Implementing cost reduction strategies to improve operational efficiency and maintain margins.
- Regulatory Compliance: Ensuring compliance with all regulatory requirements to minimize risks related to product approvals.
| Risk Factor | Description | Impact |
|---|---|---|
| Industry Competition | High competition from established players and new entrants. | Market share pressure and pricing strategies. |
| Regulatory Changes | Changes in healthcare regulations affecting approvals. | Potential delays in product launches. |
| Market Conditions | Volatile economic conditions affecting spending. | Decline in consumer discretionary spending. |
| Operational Risks | Supply chain issues and manufacturing inefficiencies. | Increased operational costs. |
| Financial Risks | Fluctuations in foreign exchange rates and high debt. | Pressure on liquidity and cash flow. |
| Strategic Risks | Reliance on key products and markets. | Vulnerability to demand fluctuations. |
Future Growth Prospects for Masimo Corporation (MASI)
Future Growth Prospects for Masimo Corporation
Analysis of Key Growth Drivers
Product Innovations: The company has introduced several new products aimed at enhancing its healthcare segment. Notably, revenues from the healthcare segment reached $343.3 million for the three months ended September 28, 2024, compared to $307.8 million for the same period in 2023, reflecting a growth of 11.5% year-over-year.
Market Expansions: The non-healthcare segment generated $161.3 million in revenues for the three months ended September 28, 2024, down from $171.1 million in 2023. However, strategic partnerships with brands like Bowers & Wilkins™ and Denon™ are anticipated to bolster future growth in this sector.
Future Revenue Growth Projections and Earnings Estimates
For the full year 2024, total revenue is projected to be approximately $2.0 billion, with a slight decline from $2.04 billion in 2023. Net income for the nine months ended September 28, 2024, was reported at $44.7 million with net income per diluted share of $0.82.
| Financial Metric | 2024 (Projected) | 2023 (Actual) |
|---|---|---|
| Total Revenue | $2.0 billion | $2.04 billion |
| Net Income | $44.7 million | $47.6 million |
| Net Income per Diluted Share | $0.82 | $0.88 |
Strategic Initiatives and Partnerships
The company is actively pursuing strategic partnerships to enhance its market presence. The launch of new endorsements for its non-healthcare products is expected to attract a broader consumer base. Additionally, the ongoing focus on cost reduction strategies is projected to improve overall profitability.
Competitive Advantages
Technological Edge: The company has a strong portfolio of patented technologies that provide a competitive advantage in the healthcare market. As of September 28, 2024, intangible assets related to customer relationships and acquired technologies were valued at $169.0 million and $115.3 million, respectively.
Strong Cash Position: As of September 28, 2024, cash and cash equivalents stood at $158.5 million, providing ample liquidity to fund future growth initiatives.
Conclusion
With its robust product pipeline, strategic partnerships, and solid financial position, the company is well-positioned to capitalize on growth opportunities in both its healthcare and non-healthcare segments.
Masimo Corporation (MASI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Masimo Corporation (MASI) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Masimo Corporation (MASI)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Masimo Corporation (MASI)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.